[The Prognostic Factors for AML Children with CBFβ/MYH11 Positive].

Objective: To analyze the prognostic factors of AML children with CBFβ/MYH11 positive.

Methods: Twenty-eight children with CBFβ/MYH11 positive treated in our hospital from May 2012 to June 2018 were selected, the clinical data and curative were analyzed and evaluated.

Results: Five-year OS and 5-year EFS rate of CBFβ/MYH11 positive AML children was 76.8% and 64.0% efficacy, respectively. Univariate analysis results showed that the OS rate of CBFβ/MYH11 positive AML children with WBC<60.0×10/L was 86.5%, which was significantly higher than those of CBFβ/MYH11 positive AML children with WBC≥60.0×10/L (χ=3.891, P<0.05). The EFS rate of CBFβ/MYH11 positive AML children with WBC<60.0×10/L was 76.0%, which was significantly higher than those of AML children with WBC≥60.0×10/L (χ=4.588, P<0.05). The EFS rate of CBFβ/MYH11 positive AML children with XRCC-Thr241Met wild type was 77.9%, which was significantly higher than those of AML children with XRCC-Thr241Met variant (χ=3.960, P<0.05). Cox multivariate survival analysis results showed that WBC level at initial diagnosis was the risk factor for OS rate. The WBC level and XRCC-Thr241Met type at initial diagnosis were the risk factors for EFS rate.

Conclusion: WBC level and XRCC-Thr241Met genotype at initial diagnosis are the major affecting factors for prognosis of AML children with CBFβ/MYH11 positive.